We bring to your notice a new website where you can buy priligy australia at a low cost with fast delivery to Australia.

Justtrade.in

Ranbaxy Q4 Net profit down at Rs. 777.8 cr.
April 25, 2009
Ranbaxy Limited came out with its Fourth-quarter FY09 results which were far below the Market expectations; its Total income fell by 16% year on year to Rs. 802.2cr. whereas its net profit fell to Rs.- 777.8cr.

Key Highlights

× Ranbaxy posted a consolidated loss Rs. 761cr. for Stock Statistics (as on 23 Apr 2009)
Q1CY09. This was the third straight quarterly loss for the company which is now owned by Daiichi Sankyo. × US has banned 30 drugs manufactured at two of the Market Cap (cr.) Ranbaxy’s Indian Plant. US had also halted the × The consolidated sales fell by 4% at Rs. 1558cr. with EPS (TTM) sales in developed marked contracting by 6%. × Forex losses stood at Rs. 1130.6cr. Rs 84.5cr in forex contract that expired during the quarter and Rs Book Value per share 127.3cr in translational losses on overseas loans. In Face Value addition, it incurred Rs. 918.8cr mark to market losses on hedges or options outstanding at the end of quarter. Excluding forex losses, the company’s net loss stood at Rs. 26cr. during the quarter compared with Rs. 85cr. last year. The company expects forex loss to continue as sales have dropped in all key markets, in dollar values the sales in US are down by 30% and in rupee terms the sales are down by 14%. × The drug maker entered into agreement with Daiichi Sankyo to sell hypertension drug Olmesartan in India. This will be the Daiichi Sankyo first drug to be launched by Ranbaxy in × Ranbaxy will soon start third phase studies on its novel anti malaria drug in India and in Standalone
(Rs.cr) (Rs.cr) (Rs.cr) %

Abhishek Gupta,

Net Sales
Net Sales
Net Sales
Company Name
1815.4 1.8
1281.8 18.4
5988 -2.6
5256.4 -1.4
3899.9 -2.5

Disclaimer:
This document has been prepared by Bajaj Capital Centre for Investment Research (BCCIR), a unit
of Bajaj Capital Limited.
This document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or
as an official confirmation of any transaction.
The information contained herein is from publicly available data or other sources believed to be reliable. We do
not represent that information contained herein is accurate or complete and it should not be relied upon as such.
This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis
for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient
of this document should make such investigations as it deems necessary to arrive at an independent evaluation
of an investment in the securities of companies referred to in this document (including the merits and risks
involved). The investment discussed or views expressed may not be suitable for all investors.
Affiliates of BCL may have issued other reports that are inconsistent with and reach to a different conclusion from
the information presented in this report.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or
resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject BCL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. BCL will not treat recipients as customers by virtue of their receiving this report.

Source: http://justtrade.in/download/stockreview/ran_q4.pdf

Dear parents, students and guardians:

Berkshire School – Student Health Service Medication Letter Dear Parents, Students and Guardians, Berkshire School’s medication policy has been developed to insure the health and safety of all students. Please read and review this policy thoroughly with your child before beginning school. The Commonwealth of Massachusetts requires that we have a written order for each prescription

Microsoft word - 5121583.doc

Biolife Italiana Srl Technical Sheet N °5121583 BE –1(P) 09/2012 page 1/ 2 TSC AGAR BASE D-CYCLOSERINE ANTIMICROBIC SUPPLEMENT D-CYCLOSERINE 4-MUP SUPPLEMENT Basal medium and selective supplements for the enumeration of C.perfringens in foodstuffs according to ISO 7973 and ISO 15213 TYPICAL FORMULAS TSC Agar Base (g/L) D-Cycloserine Antimicrobic S

Copyright © 2010-2014 Medical Science